Gal-3 was recently reported to be associated with an increase in drug resistance in chronic myeloid leukaemia (CML) mediated by the bone marrow microenvironment [36]. The gene discussed is LGALS3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.